Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




CSF Glucose Unaltered in Patients With Dementia

By LabMedica International staff writers
Posted on 14 Dec 2022

A plethora of the pathological processes of many dementia disorders begin several years before the clinical expression of the diseases, and for that reason it is important to discover new biomarkers and methods to detect these processes at an early stage. More...

Glucose is transported from the blood, through the blood brain barrier (BBB), and into the interstitial space, where it is made available for metabolism by astrocytes and neurons. Normally, there is a close relationship between cerebrospinal fluid (CSF) and plasma glucose concentrations, and the ratio ranges between 0.5 and 0.8, but the ratio may change in different pathological conditions.

Clinical Scientists at the Copenhagen University Hospital Rigshospitalet (Copenhagen, Denmark) and their colleagues collected CSF and plasma samples from patients referred for diagnostic evaluation. The samples were taken from 446 patients (Alzheimer’s Disease (AD) (n=320), vascular dementia (VaD) (n=64), frontotemporal dementia (FTD) (n=27) and dementia with Lewy bodies (DLB) (n=35)), and 130 healthy controls (HC) (healthy subjects (HS) (n=34), non-demented HS (n=96)).

CSF was collected in 5 mL polypropylene tubes, transported at room temperature, and analyzed on a Radiometer ABL instrument (Radiometer Medical ApS, Brønshøj, Denmark) within an hour after sampling. Plasma was collected in 2 mL Greiner bio-one VACUETTE tubes with Sodium Fluoride/Potassium Oxalate (Greiner, Kremsmünster, Austria), transported at room temperature, and analyzed on a COBAS 8000 instrument (Roche Diagnostics, Indianapolis, IN, USA) within three hours after sampling.

The investigators reported that no significant differences in CSF and plasma glucose levels between the dementia group and HC were found. Furthermore, no significant difference in the CSF/plasma glucose ratio was identified. When investigating CSF glucose, plasma glucose and the CSF/plasma glucose ratio for the different etiologies within the dementia group, no significant differences were found. In addition, no statistically significant differences were found in the relationship between age and CSF glucose, plasma glucose and the CSF/plasma glucose ratio.

The authors concluded that despite severe reductions in the glucose metabolism in the brain of patients with dementia disorders, CSF and plasma glucose levels and the CSF/plasma-glucose ratio do not reflect this hypometabolism, and do not differentiate between dementia of different etiologies. For that reason, it is unlikely that they will have diagnostic potential in a mixed memory clinic setting. The study was published on December 8. 2022 in the journal Clinical Biochemistry.

Related Links:
Copenhagen University Hospital Rigshospitalet
Radiometer Medical
Greiner
Roche Diagnostics


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.